Alpine Immune Sciences
Seattle
About Alpine Immune Sciences
Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $475.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2023)
- Ticker: nasdaq:ALPN
- Website: alpineimmunesciences.com
- Phone: (206)441-5062
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/alpine-immune-sciences-102828 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.